Evaluation of pharmacokinetic studies: Is it useful to take into account concentrations below the limit of quantification?

Pharmaceutical Research

Volumn 13, Issue 6, 1996, Pages 839-845

  Humbert, Henri ^a   Cabiac, Marie Danièle ^a   Barradas, José ^a   Gerbeau, Christophe ^a  

^a Laboratoires Sandoz   (France)

Author keywords

Accuracy; Limit of quantification; Pharmacokinetics; Precision

Indexed keywords

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; VOLUNTEER;

AREA UNDER CURVE; CROSS-OVER STUDIES; HALF-LIFE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; THERAPEUTIC EQUIVALENCY;

EID: 0029992832     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016088609005     Document Type: Article

References (15)

1. A. B. J. Nix, D. W. Wilson. Assay detection limits: concept, definition and estimation. Eur. J. Clin. Pharmacol 39:203-206 (1990).
2. V. P. Shah, K. K. Midha, S. Dighe, I. J. McGilveray, J. P. Skelly, A. Yacobi, T. Layloff, C. T. Viswanathan, C. E. Cook, R. D. McDowall, K. A. Pittman, S. Spector. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur. J. Drug Metab. 16:249-255 (1991).
3. J. O. Westgard, P. L. Barry. Cost effective quality control: managing the quality and productivity of analytical processes, AACC Press, Washington DC, 1986, pp. 33-64.
4. A. J. Jackson. Inappropriate inclusion of non-quantifiable plasma concentrations in the estimation of extent of absorption. Biopharm. Drug Disp. 13:629-634 (1992).
5. P. Francheteau, J. L. Steimer, C. Dubray, D. Lavène. Mathematical model for in vivo pharmacodynamics integrating fluctuation to the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922. J. of Pharm. and Biopharm. 19(3):287 (1991).
6. H. Zehender, M. D. Cabiac, J. Denouël, J. Faergemann, P. Donastsch, K. Kutz, H. Humbert. Elimination kinetics of terbinafine (lamisil) from human plasma and tissues following multiple dose administration of 250 mg daily during four, twelve and fourty-eight weeks and comparison with three main metabolites. Drug Invest. 8(4):203-210 (1994).
7. D. A. Graves. Failure of single dose kinetics to predict steady-state. Drug Intell. Clin. Pharm. 22:917-918 (1988).
8. H. T. Karnes, G. Shiu, V. P. Shah. Validation of bioanalytical methods. Pharm. Res. 8:421-426 (1991).
9. W. A. Sadler, M. H. Smith. Use and abuse of imprecision profiles: some pitfalls illustrated by computing and plotting confidence intervals. Clin. Chem. 36:1346-1350 (1990).
10. M. Gibaldi, D. Perrier. Pharmacokinetics, 2nd edition, Marcel Dekker Inc, New-York, 1983.
11. L. B. Sheiner. ELSFITT (Version 3.1). A program for the extended least Squares fit to individual pharmacokinetic data. Users manual. April 1985. Technical report of the division of Clinical Pharmacology, University of California, San Francisco, CA 94143, USA.
12. D. A. Graves, C. S. Locke, Jr., K. T. Muir, R. P. Miller. The influence of assay variability on pharmacokinetic parameter estimation. J. Pharmacokin. Biopharm. 17:571-592, 1989.
13. H. Passing, W. Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I. J. Clin. Chem. Clin. Biochem. 21:709-720, 1983.
14. F. Y. Bois, T. N. Tozer, W. W. Hauck, M. L. Chen, R. Patnaik, R. L. Williams. Bioequivalence: performance of several measures of extent of absorption. Pharm. Research 11(5):715 (1994).
15. S. E. Tett, D. J. Cutler. Apparent dose-dependence of chloroquine pharmacokinetics due to limited assay sensitivity and short sampling times. Eur. J. Clin. Pharmacol. 31:729-731 (1987).